Genflow Biosciences Plc ( (GB:GENF) ) has provided an announcement.
Genflow Biosciences Plc has made significant progress in its patent application for SIRT6 variants, a potential breakthrough in age-related disease therapeutics, following a positive review from the European Patent Office. This advancement strengthens Genflow’s intellectual property position in SIRT6-based therapeutics and supports its mission to develop treatments for age-related diseases, signaling a strategic step forward for the company’s operations and market positioning.
More about Genflow Biosciences Plc
Founded in 2020, Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D facilities in Belgium. It focuses on pioneering gene therapies aimed at slowing down the aging process to promote longer and healthier lives. The company is known for its lead compound, GF-1002, which targets the SIRT6 gene and is preparing for clinical trials to address Metabolic Dysfunction-Associated Steatohepatitis (MASH), a prevalent chronic liver disease.
YTD Price Performance: 7.56%
Average Trading Volume: 1,061,068
Technical Sentiment Consensus Rating: Buy
See more insights into GENF stock on TipRanks’ Stock Analysis page.